Wedge Capital Management L L P NC Purchases 6,614 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Wedge Capital Management L L P NC boosted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 9.8% during the second quarter, Holdings Channel reports. The institutional investor owned 73,900 shares of the specialty pharmaceutical company’s stock after acquiring an additional 6,614 shares during the quarter. Wedge Capital Management L L P NC’s holdings in Supernus Pharmaceuticals were worth $2,329,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Financial Management Professionals Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 1st quarter valued at approximately $30,000. Versant Capital Management Inc boosted its stake in shares of Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,109 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Supernus Pharmaceuticals during the first quarter worth about $41,000. GF Fund Management CO. LTD. bought a new stake in shares of Supernus Pharmaceuticals during the fourth quarter valued at approximately $42,000. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Supernus Pharmaceuticals during the first quarter valued at approximately $46,000.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, Director Bethany Sensenig sold 5,369 shares of the business’s stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $42.25, for a total value of $226,840.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Timothy C. Dec sold 11,780 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $44.49, for a total transaction of $524,092.20. Following the sale, the chief financial officer directly owned 1,246 shares of the company’s stock, valued at approximately $55,434.54. This trade represents a 90.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 246,506 shares of company stock worth $10,696,144 in the last ninety days. Company insiders own 8.80% of the company’s stock.

Analyst Ratings Changes

SUPN has been the topic of a number of analyst reports. Piper Sandler boosted their price objective on Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a “neutral” rating in a research note on Friday, August 29th. Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 17th. Wall Street Zen raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Finally, Cantor Fitzgerald increased their price target on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an “overweight” rating in a report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $43.00.

Supernus Pharmaceuticals Price Performance

Supernus Pharmaceuticals stock opened at $46.04 on Monday. The stock has a market capitalization of $2.58 billion, a PE ratio of 40.03 and a beta of 0.79. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $46.78. The firm has a 50 day simple moving average of $40.67 and a 200-day simple moving average of $35.08.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.